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ABSTRACT  
Background: Narcotics and psychoactive substances abuse, particularly by intravenous route, currently is a 
major health problem affecting young Indonesian people. Consequently, there is an increasing incidence of blood-
borne viral diseases, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV) infections. 
This study was aimed to investigate the prevalence of HCV and HIV co-infection among narcotics abusers in 
Pondok Indah Hospital, Jakarta.  
Method: This was a cross-sectional study in Pondok Indah Hospital, Jakarta using patients’ medical records. 
Data from patients with the diagnosis of mental and behavioral disorders due to various psychoactive 
substances and HIV-related diseases were retrieved to obtain demographic characteristics, history of drug abuse 
and serological testing. Patients were excluded if there were another organic mental disorders found or a history of 
blood transfusion prior to infection.  
Results: There were 157 cases of drug abuse collected between January 2000 and May 2005, 85.4% were men 
and their median age was 24 years old. The peak age group was 21-25 years old. Injection drug users (IDUs) 
were found in 72% of cases. Anti-HCV total antibody was found in 45.2% cases, including 2 nonIDUs, while 
anti-HIV antibody and combined anti-HCV/anti HIV antibodies were found in 13.4% and 7.6% cases, 
respectively. Anti-HCV positive patient are significantly younger than anti-HCV negative patients (27.9 + 8.2 
vs. 23.7 + 4.4 years, p < 0.001), while the duration of use was not significantly correlated with HCV infection. 
Neither age nor duration of use was statistically significant with the presence of anti-HIV antibody. However, 
there is a significant correlation between the duration of drug abuse with HCV and HIV co-infection (6.0 + 3.0 
vs. 4.1 + 2.8 years, p = 0.027).  
Conclusion: The prevalence of HCV and HIV co-infection among narcotics abusers in Pondok Indah 
Hospital was 7.6%. The emerging cases of hepatitis C and HIV infections during the last several years was 
significantly related to the increasing numbers of narcotics abusers.  
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INTRODUCTION 
Narcotics and additive substances abuse is one of  
the most important community health problems in  
Indonesia, especially in large cities like Jakarta.  
Injection drug users (IDUs) in particular, are very  
susceptible to blood-borne viral infections. Besides  
hepatitis B, IDUs are also prone to hepatitis C virus  
(HCV) and human immunodeficiency virus (HIV)  
infections. HCV and HIV are the most commonly 
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transmitted pathogens to drug users through 
the multi-person use of syringes and needles. Viral- 
contaminated blood may be transferred to the next user 
because a small residue of blood always remains in 
the needle and syringe.1 
The incidence of HCV infection among intravenous  
drug abusers varies between 31% and 98% worldwide,  
thus, making the IDUs a potential reservoir of HCV in  
the community.2 In Jakarta, hepatitis B virus (HBV) and 
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hepatitis C (virus) infections, either alone or as 
co-infection, had been reported to be much higher in IDUs  
compared to the general populations.3 The exact  
prevalence of HCV or HIV infections in IDUs was not  
known; the first co-infection of HCV and HIV in Jakarta  
probably took place in 1999 and it was increasing  
thereafter.4 
Before 2000, cases of HCV and HIV infections were  
rare and no cases of HCV/ HIV co-infection in Pondok  
Indah Hospital, Jakarta. Between January 2000 and April  
2001, the hospital opened an exclusive ward dedicated  
for narcotic abusers. However, many objections then came  
up from the surroundings, and so it was closed. During  
this short period of time, a substantial number of patients  
had come for detoxification. Currently, the service is still  
available but the number of patients has decreased. The  
objective of this study was to investigate the profile of  
HCV and HIV infections among narcotics abusers in  
Pondok Indah Hospital, Jakarta. 
 
METHOD 
This was a cross-sectional study in narcotics and  
substance abusers, who came to Pondok Indah  
Hospital, between January 2000 and May 2005. Patient  
records were retrieved from Medical Record Department  
using the codes of International Statistical Classification  
of Disease and Related Health Problem 10th Revision  
(ICD-10)5 of mental and behavioral disorders due to  
use of opioids (F11), cannabinoids (F12), sedatives or  
hypnotics (F13), cocaine (F14), other stimulants (F15),  
hallucinogens (F16), tobacco (F17), volatile solvents  
(F18), and other psychoactive substances (F19). Cases  
were also searched in patients with HIV disease  
resulting in unspecified infectious or parasitic  
disease (B20.9), acute HIV infection syndrome (B23.0),  
unspecified human immunodeficiency virus (B24).  
Patients were excluded if there was an underlying  
organic mental or behavioral disorders, suicidal tendency,  
other chronic diseases that used opiates as painkiller,  or  
patients having blood transfusion as the method of  
transmission. 
Blood sample were withdrawn from all patients. HCV  
and HIV antibodies were assayed by enzyme-linked  
immunosorbent assay (ELISA) method at our hospital  
laboratory. 
 
RESULTS 
There were 171 cases collected between January 2000  
and May 2005; one case of HIV infection by blood  
transfusion and thirteen cases of drug intoxication were  
excluded i.e. two cases of heart disease, one case of lung 
cancer, one case of hyperemesis in pregnancy, and nine 
cases of organic mental disorder (depression, 
anxiety, acute psychosis). The prevalence in men was six 
times more frequent than women. Eighty percents of the 
patients are below 30 years old with the highest peak in 
21-25 years old. 
Intravenous route was primarily used by 113 or 72%  
of patients, either as single method, combined with  
inhalation and/oral route (Table 1). Inhalation and oral  
routes were used by 34 (21.6%) and 10 (6.4%) patients,  
respectively. The most frequent drug used by  
intravenously was putauw (91.6%) followed by  
shabu-shabu (5.6%), other opiates (1.9%), and cocaine  
(0.9%). 
Hepatitis C antibody was found in 71 (45.2%), while 
anti-HIV was found in 21 (13.4%). HCV and HIV 
co-infection was found in 12 (7.6%) patients, i.e. 57.1% 
of HIV patients or 16.9% of HCV infection cases. 
Intravenous route is strongly correlated with the infection 
of HCV, HIV or both (table 2). 
Patients with anti-HCV antibody positive were  
significantly younger than their negative counterparts. Anti- 
HCV antibody was already found in a patient with a short  
duration of drug abuse (4 months), while the minimum  
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Table 1. Patient’s Characteristic (N=157) 
Characteristic N % 
  
134 85.4 
Sex 
 Male 
 Female 23 14.6 
  
  
  
  
 26 16.6 
 64 40.8 
 36 22.9 
 17 10.8 
    6    3.8 
    4    2.5 
    2    1.3 
Age (years old) 
Median, 24 years old 
Minimum, 16 years old 
Maximum, 54 years old 
 16-20  
 21-25  
 26-30  
 31-35  
 36-40  
 41-45  
 46-50  
 > 50      2    1.3 
Duration of drug use 
Mean, 4.3 years 
Minimum, 4 months 
Maximum, 22 years 
  
  
10   6.4 
25 15.9 
77 49.0 
10   6.4 
24 15.3 
  9    5.7 
Method of use 
 Oral 
 Inhalation 
 Intravenous 
 Intravenous and oral 
 Intravenous and inhalation 
 Oral and inhalation 
 Intravenous, oral, and inhalation    2    1.3 
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hepatocellular carcinoma (HCC)8 and liver-related  
Table 2. Serological Testing and the Method of Drug Abuse mortality.9    However, HCV has little or no effect on 
Serology 
Anti-HCV total antibody 
   Intravenous route 
   Non intravenous route 
Anti-HIV antibody 
   Intravenous route 
   Non-intravenous route 
HCV and HIV co-infection  
    Intravenous route 
   Non intravenous route 
Positive  Negative   p ( 2) 
 
69 44 < 0.001* 
2 42 
 
21 92 0.001* 
0 44 
 
12 101 0.012* 
0 44 
the response to antiretroviral therapy (ART), or on 
immunological, virological and HIV-related clinical 
disease progression.10 
The prevalence of HCV/HIV co-infection (7.6%) and  
the proportion of anti-HCV-positive among HIV-positive  
patients (57.1%) in our study are lower than many other  
studies. A community-based survey among 379 IDUs in  
Sichuan Province of China found that the prevalence of 
* Significant at p < 0.05 level 
duration of drug abuse in anti-HIV positive patients was  
one year. The duration of drug abuse was not correlated  
with the presence of HCV or HIV antibody alone, but it 
is statistically significant with HCV/HIV co-infection 
(table 3). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
DISCUSSION 
HCV transmission occurs primarily by exposure to 
infected blood. However, some other routes of 
transmission might also exist, like sexual or household  
exposure to an infected contact.2 In addition, IDUs could  
also have other behavioral risk, like tattooing, body 
piercing, and unsafe sexual intercourse, which were not 
addressed in this study. 
Several studies have suggested that patients with HCV/  
HIV co-infection progress more rapidly to liver cirrhosis 
and liver cancer. In HCV-infected patients, HIV 
accelerates the course of HCV-associated liver disease 
progression.   Both   HBV/HIV   and   HCV/HIV 
co-infection is associated with increased liver fibrosis 
progression6 and increased rate of liver cirrhosis,7 
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HCV and HIV co-infection was 11.3%.11 Other study in 
urban population of active injection drug users showed 
than 60% to 80% of those with HIV are also infected  
with HCV.12 A survey of adults within the multicenter  
AIDS Clinical Trial Group (ACTG) suggested an overall 
prevalence of 16% to 20% in the Unites States among 
those infected with HIV.13 In Brazil, a study in 1,457 HIV- 
positive patients showed that 17.7% of them were also 
HCV-positive.14 
In Canada, the prevalence of anti-HCV antibodies was 
81.6% among a cohort of 1,345 IDUs. Among subjects 
who were HIV positive, 95% were HCV seropositive,  
while among HIV negative subjects, 78% were HCV 
seropositive (p < 0.001). In contrast to our study, HCV  
seropositive IDUs in that study were significantly older 
than HCV seronegative IDUs (median age 35 vs.  
25 years old). HCV seropositive subjects reported 
injecting for a median of 14 years, whereas seronegative  
subjects had been injecting for a median of only 3 years.15  
 The low rate of HCV infection in HIV patients could  
be due to under detected HCV antigen or antibody in our  
subjects. According to the latest recommendation, all HIV- 
infected patients should be screened using a third- 
generation anti-HCV antibody test. A positive result should  
be followed by evaluation for the presence of HCV-RNA, 
which indicates active disease. A negative anti-HCV 
antibody could be due to acute HCV (diagnostic window)  
or a blunted immune response. In this case, HCV-RNA  
should be measured.10 The measurement of HCV-RNA  
in our hospital is not routinely done since the cost is very  
expensive   for   the   patients   and   their   families.  
 The presence of co-infection of HCV and HIV brings 
a special challenge in the clinical management of 
the patients. After the introduction of new antiretroviral  
agents, survival rates of HIV-infected patients have been  
increased worldwide. However, treatment with ART might 
possess a risk of hepatic toxicity. Since HIV 
co-infection accelerates the progression of liver disease  
caused by HCV, the clinical management and treatment  
of HCV should become a priority in medical institution  
receiving HIV-positive patients.16 The European  
Association for the Study of the Liver (EASL) has 
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recently recommended the combination of pegylated 
interferon alpha and ribavirin as the treatment of choice 
for HCV infection in HIV-infected patients.10 
 
CONCLUSION 
The prevalence of HCV and HIV co-infection among 
narcotics abusers in Pondok Indah Hospital was 7.6%. 
The emerging cases of hepatitis C and HIV infections, 
during the last five years showed significant relation to 
increasing number of narcotics abusers. 
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